SAMO

SAMO is an Uzbekistan-based pharmaceutical company focused on the development and manufacturing of solid-dose and related generic medicines, including tablets, powders, and antiseptic products. The company markets more than 40 products and appears to operate as a commercial-stage manufacturer rather than a clinical-stage biotech innovator. Publicly visible products include clopidogrel, ketotifen, acetylsalicylic acid, ibuprofen, paracetamol, diazolin, and calcium D3 formulations. SAMO presents itself as part of the UGP group of companies and emphasizes quality systems aligned with ISO 9001:2015 and GMP requirements. The business appears primarily oriented toward domestic and regional pharmaceutical supply and export of its own manufactured products.